Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
type
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label attachment file name title previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1126022

	registered interest
	date	13/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	National Institute for Health and Care Excellence
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will expedite the process by which the NICE publishes its decisions.
	tabling member constituency	Stroud
	tabling member printed	Dr David Drew
	type	WrittenParliamentaryQuestion
	uin	253483
	answer	answer is ministerial correction date of answer 21/05/2019 answer text <p>The Government wants patients to be able to benefit from access to effective new treatments as quickly as possible.</p><p>Through its technology appraisal and highly specialised technologies guidance, the National Institute for Health and Care Excellence (NICE) makes authoritative, evidence-based recommendations on whether medicines and other treatments represent a clinically and cost effective use of National Health Service resources. NHS organisations are legally required to make funding available for NICE recommended treatments, usually within three months of final guidance.</p><p>Wherever possible, NICE currently aims to publish recommendations on new drugs as soon as possible after licensing, with draft guidance on cancer drugs published in advance of licensing. The 2019 Voluntary Scheme for Branded Medicines Pricing and Access includes a commitment to faster NICE assessments of new medicines, with timelines for non-cancer drugs to match those for cancer drugs, subject to the evidence base for the product being sufficiently developed.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 21/05/2019 10:58:38 answering member 4455 label Biography information for Seema Kennedy
	tabling member	252 label Biography information for Dr David Drew

1142187

	registered interest
	date	25/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	National Institute for Health and Care Excellence
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he publish the names of the members of the (a) steering group, (b) working group and (c) each of the task and finish groups for NICE’s review into its methods and processes.
	tabling member constituency	Scunthorpe
	tabling member printed	Nic Dakin
	type	WrittenParliamentaryQuestion
	uin	282320
	answer	answer is ministerial correction date of answer 09/09/2019 answer text <p>It has not proved possible to respond to the hon. Member in the time available before Prorogation.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 09/09/2019 17:52:02 answering member 4380 label Biography information for Jo Churchill
	tabling member	4056 label Biography information for Nic Dakin

1145510

	registered interest
	date	24/09/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	National Institute for Health and Care Excellence
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will publish the roles of the members of the (a) steering group, (b) working group and (c) each of the task and finish groups for NICE's review into its methods and processes.
	tabling member constituency	Scunthorpe
	tabling member printed	Nic Dakin
	type	WrittenParliamentaryQuestion
	uin	290336
	answer	answer is ministerial correction date of answer 30/09/2019 answer text <p>The steering group and working group members and their roles are published on the National Institute for Health and Care Excellence (NICE) website at the following link:</p><p><a href="https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/changes-to-health-technology-evaluation" target="_blank">https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/changes-to-health-technology-evaluation</a></p><p>NICE has advised the Department that it plans to publish the names of those people involved in the task and finish groups on its website as soon as they are confirmed.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 30/09/2019 17:05:30 answering member 4380 label Biography information for Jo Churchill
	tabling member	4056 label Biography information for Nic Dakin

1204449

	registered interest
	date	16/06/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	National Institute for Health and Care Excellence
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve the methodology used by NICE to appraise combination therapies in the ongoing NICE Methods Review.
	tabling member constituency	Nottingham North
	tabling member printed	Alex Norris
	type	WrittenParliamentaryQuestion
	uin	59876
	answer	answer is ministerial correction date of answer 07/07/2020 answer text <p>The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the methods it uses in developing its guidance. While NICE is currently undertaking a review of its methods for health technology evaluation, the review is not considering combination treatments as a specific topic.</p><p>Commercial and policy-related challenges for combination treatments are being explored in other projects in line with the commitments in the Voluntary Scheme for Branded Medicines Pricing and Access. As stated in the Scheme, the Department and NHS England and NHS Improvement will support the Association of the British Pharmaceutical Industry’s efforts to find solutions to these challenges.</p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 07/07/2020 15:03:10 answering member 4380 label Biography information for Jo Churchill previous answer version 31043 answering member constituency Bury St Edmunds answering member printed Jo Churchill answering member 4380 label Biography information for Jo Churchill
	tabling member	4641 label Biography information for Alex Norris

1271496

	registered interest
	date	15/12/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	National Institute for Health and Care Excellence
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the level of patient involvement in the NICE process for evaluating and approving new medicines and treatment; and whether there are plans under the ongoing Methods Review to adjust that level of involvement.
	tabling member constituency	Nottingham North
	tabling member printed	Alex Norris
	type	WrittenParliamentaryQuestion
	uin	130207
	answer	answer is ministerial correction date of answer 27/01/2021 answer text <p>The National Institute for Health and Care Excellence (NICE) is an independent body and is therefore responsible for its own methods and processes for evaluations and approving new medicines and treatments. Consultee organisations for NICE’s technology appraisals include national groups representing patients and carers.</p><p>NICE has had patient involvement throughout its methods and process review, including a specific workstream led by patient representatives and senior NICE staff. Patient groups are also represented on its Methods Review Working Group.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 27/01/2021 15:29:38 answering member 4380 label Biography information for Jo Churchill previous answer version 72723 answering member constituency Bury St Edmunds answering member printed Jo Churchill answering member 4380 label Biography information for Jo Churchill
	tabling member	4641 label Biography information for Alex Norris

1416468

	registered interest
	date	25/01/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	National Institute for Health and Care Excellence
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 11 January 2022 to Question 96910 on National Institute for Health and Care Excellence, how many oncology technical appraisals have been rescheduled in the last six months directly as a result of NICE operational challenges; and what the average time taken has been to reschedule those appraisals.
	tabling member constituency	Bolton West
	tabling member printed	Chris Green
	type	WrittenParliamentaryQuestion
	uin	111625
	answer	answer is ministerial correction date of answer 31/01/2022 answer text <p>The National Institute for Health and Care Excellence (NICE) has rescheduled one appraisal of an oncology technology in the last six months for operational reasons. NICE’s appraisal of pembrolizumab in combination with chemotherapy for neoadjuvant treatment of triple negative breast cancer has been delayed by approximately three months due to the volume of topics in its work programme. NICE’s final guidance is expected to be published in November 2022.</p> answering member constituency Charnwood answering member printed Edward Argar question first answered 31/01/2022 17:57:59 answering member 4362 label Biography information for Edward Argar
	tabling member	4398 label Biography information for Chris Green

1461042

	registered interest
	date	10/05/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	National Institute for Health and Care Excellence
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether they plan to publish the names of the organisations which took part in the early engagement programme with the National Institute for Health and Care Excellence before the publication of its new methods and processes for its health technology evaluation programme.
	tabling member printed	Lord Hunt of Kings Heath
	type	WrittenParliamentaryQuestion
	uin	HL69
	answer	answer is ministerial correction date of answer 20/05/2022 answer text <p>While there was no specific early engagement programme, the National Institute for Health and Care Excellence’s (NICE) recent review of its methods and processes for health technology evaluation was overseen by a steering group and working group. The organisations which participated in these groups are as follows:</p><p>Centre for Health Technology Evaluation, NICE;</p><p>Centre for Guidelines, NICE;</p><p>Centre for Health Economics, University of York;</p><p>NHS England and NHS Improvement;</p><p>The Office for Life Sciences;</p><p>The Department of Health and Social Care;</p><p>NICE appraisal committee;</p><p>British In Vitro Diagnostics Association;</p><p>The Association of the British Pharmaceuticals Industry;</p><p>The Psoriasis and Psoriatic Arthritis Alliance;</p><p>The British Medical Journal Technology Assessment Group;</p><p>The Ethical Medicines Industry Group;</p><p>The BioIndustry Association;</p><p>Genetic Alliance;</p><p>ReCor Medical UK, Association of British HealthTech Industries;</p><p>School of Health and Related Research, the University of Sheffield;</p><p>Alzheimer's Research UK.</p> answering member printed Lord Kamall question first answered 20/05/2022 09:58:16 answering member 4909 label Biography information for Lord Kamall
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1461043

	registered interest
	date	10/05/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	National Institute for Health and Care Excellence
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what work they are currently undertaking, if any, to identify topics which require modular updates by the National Institute for Health and Care Excellence and which may be facilitated for entry to managed access.
	tabling member printed	Lord Hunt of Kings Heath
	type	WrittenParliamentaryQuestion
	uin	HL70
	answer	answer is ministerial correction date of answer 25/05/2022 answer text <p>The National Institute for Health and Care Excellence’s (NICE) outline for future modular updates was published in the January 2022 board paper Review of methods, processes and topic selection for health technology evaluation programmes: conclusions and final update. The paper states that NICE has identified potential topics for future modular reviews, including processes to facilitate rapid entry to managed access, methods issues for digital, genomic and antimicrobial technologies and the societal value of health benefits in severe diseases and health inequalities. A copy of the paper is attached. During the implementation of NICE’s strategy 2021 to 2026, it will prioritise developing a proportionate approach to health technology appraisals and MedTech early value assessment in the next 12 months.</p> answering member printed Lord Kamall question first answered 25/05/2022 11:19:37 answering member 4909 label Biography information for Lord Kamall attachment 1 file name Review of methods, processes and topic selection for health technology evaluation programmes conclusions and final update (1).docx title NICE
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1653811

	registered interest
	date	18/07/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	National Institute for Health and Care Excellence
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that NICE’s Topic Selection Oversight Panel considers (a) clinical and (b) patient expert insights in its decision-making processes.
	tabling member constituency	Leeds North West
	tabling member printed	Alex Sobel
	type	WrittenParliamentaryQuestion
	uin	194779
	answer	answer is ministerial correction date of answer 04/09/2023 answer text <p>The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the decision-making processes that it operates.</p><p>NICE’s Topic Selection Oversight Panel (TSOP) is responsible for the selection of topics for guidance development in the Centre for Health Technology Evaluation. The group considers the available evidence as well as clinical and patient insights to apply the medicines and highly specialised technologies criteria and decide whether to route medicines to the technology appraisal or highly specialised technologies programmes, or to deselect the topic. The TSOP’s membership includes lay members to provide the perspective of patients, people who use services and carers in the selection and routing of topics. It also includes members with responsibility for providing clinical insights and expertise.</p> answering member constituency Colchester answering member printed Will Quince question first answered 04/09/2023 09:38:40 answering member 4423 label Biography information for Will Quince
	tabling member	4658 label Biography information for Alex Sobel

1654470

	registered interest
	date	19/07/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	National Institute for Health and Care Excellence
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether his Department has provided guidance to NICE on the evidence used to inform the criteria updates to its Highly Specialised Technology processes.
	tabling member constituency	Leeds North West
	tabling member printed	Alex Sobel
	type	WrittenParliamentaryQuestion
	uin	195282
	answer	answer is ministerial correction date of answer 04/09/2023 answer text <p>The Department has not issued any such guidance. The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the methods and processes that it uses in the development of its guidance, including the criteria used to determine whether topics should be routed to the technology appraisal or highly specialised technologies programmes. NICE made changes to its health technology evaluation manual in January 2022 following a comprehensive review of its methods and processes, including public consultation. As part of these changes, the eligibility criteria for the highly specialised technologies programme were clarified to make them clearer and more predictable.</p> answering member constituency Colchester answering member printed Will Quince question first answered 04/09/2023 10:12:05 answering member 4423 label Biography information for Will Quince
	tabling member	4658 label Biography information for Alex Sobel